MedTrace Logo

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

NCT05369832 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2026-02-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.

Conditions

  • Colitis, Ulcerative

Interventions

DRUG

Ozanimod

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-16
Primary Completion
2025-01-21
Completion
2025-04-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05369832 on ClinicalTrials.gov